Breast: Metastatic Clinical Trials

Showing 31-37 of 37 items
31.
32.
  • Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
  • This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1125976. The relative bioavailability of liquid service formulation and tablets will be determined. After the MTD is defined breast cancer patients with and without AKT1 mutation will be treated. The study will also assess the pharmacokinetics, biomarker status, pharmacodynamic parameters and tumor response of BAY1125976. BAY1125976 will be given daily as single oral application. Treatment will be stopped if the tumor continues to grow, if side effects, which the patient cannot tolerate, occur or if the patient decides to exit treatment.
  • Diagnoses: Breast: Metastatic, Solid Tumor/Phase I
  • Status: Recruiting
33.
34.
35.
36.
  • Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
  • RATIONALE: Early surgery may have fewer side effects and improve recovery. Palliative surgery or radiation therapy may help patients with advanced breast cancer live more comfortably. It is not yet known whether early surgery is more effective than palliative therapy for advanced breast cancer. PURPOSE: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer.
  • Diagnoses: Breast: Metastatic
  • Status: Recruiting
37.
  • Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
  • This is an open-label, dose-finding study of SRN-927 administered orally on a continuous daily dosing regimen with a PK lead-in period (dose escalation period only). The incidence of dose limiting toxicity (DLT) will be evaluated from Day -7 through the first cycle (28 days) of treatment (35 days total). Depending on safety and tolerability, patients will be assigned sequentially to escalating doses of SRN-927 using standard 3+3 design. All patients will be treated until disease progression, unacceptable toxicity, or patient withdrawal of consent.
  • Diagnoses: Breast: Metastatic
  • Status: Recruiting
Showing 31-37 of 37 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms